GlassScriptPhysician profile
Kendall Johnson
NPI 1760118160
$4,724.96
in general payments reported to CMS, 2019-2025
20 companies · $1,089 in 2025
The $1,089 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $461 · 2023: $1,429 · 2024: $1,746 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,205 · Consulting Fee: $800 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,205.17 |
| Consulting Fee | $800.00 |
| Education | $258.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $849.04 | 2024-2025 | Cabtreo, Jublia |
| Abbvie INC. | $722.45 | 2022-2025 | |
| Janssen Biotech, INC. | $492.91 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $404.64 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $391.87 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $384.81 | 2022 | |
| Genzyme Corporation | $349.33 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $271.77 | 2023-2025 | Dupixent |
| Dermavant Sciences, INC. | $240.41 | 2023-2024 | Vtama |
| Amgen INC. | $104.78 | 2023-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $100.72 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $82.99 | 2023-2025 | Sotyktu |
| Ucb, INC. | $78.01 | 2023-2025 | Bimzelx, Cimzia |
| Sanofi-Aventis U.S. LLC | $72.00 | 2025 | |
| Glaxosmithkline, LLC. | $48.98 | 2023 | Arexvy, Shingrix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $38.80 | 2024-2025 | Zoryve |
| Biofrontera INC. | $32.22 | 2024 | Rhodoled Xl, Ameluz, Xepi |
| Novartis Pharmaceuticals Corporation | $25.65 | 2024 | |
| Galderma Laboratories, L.P. | $20.41 | 2025 | Nemluvio |
| Leo Pharma INC. | $13.17 | 2024 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendall Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.